Literature DB >> 31852271

Ovarian reserve markers in women using various hormonal contraceptives.

Selma Kloeve Landersoe1, Julie Lyng Forman2, Kathrine Birch Petersen3, Elisabeth Clare Larsen1, Bugge Nøhr4, Helene Westring Hvidman1, Henriette Svarre Nielsen1, Anders Nyboe Andersen1.   

Abstract

Objectives: The aim of the study was to assess whether the ovarian reserve markers anti-Müllerian hormone (AMH) and antral follicle count (AFC) were lower among women using the progestin-only pill (POP) or levonorgestrel-releasing intrauterine system (LNG-IUS) and similar to the decrease observed in combined oral contraceptive (COC) pill users.
Methods: This retrospective study comprised 565 hormonal contraceptive users (COC, POP, LNG-IUS or contraceptive vaginal ring) and 983 non-hormonal contraceptive users, who were seen in two Danish fertility assessment and counselling clinics between 2015 and 2019. Adjusted multiple regression analysis was used to examine the differences in AMH and AFC between hormonal and non-hormonal contraceptive users.
Results: Compared with non-hormonal contraceptive users, AMH was 31.1% lower among COC users [95% confidence interval (CI) -39.6%, -25.9%; p < 0.001], 35.6% lower among POP users (95% CI -49.0%, -18.6%; p < 0.001) and 17.1% lower among LNG-IUS users (95% CI -31.4%, 0.002%; p = 0.052); no significant differences were seen among vaginal ring users. Compared with non-hormonal contraceptive users, AFC was 31.3% lower among COC users (95% CI -35.0%, -25.3%; p < 0.001) and 29.7% lower among POP users (-39.1%, -17.9%; p < 0.001); no significant differences were seen among LNG-IUS or vaginal ring users. Ovarian volume was more than 50% reduced among COC and vaginal ring users (p < 0.001) but was unchanged among POP and LNG-IUS users.
Conclusion: Assessment of ovarian reserve markers among users of all types of hormonal contraception should be interpreted cautiously and the type of contraceptive method considered.

Entities:  

Keywords:  Anti-Müllerian hormone (AMH); LNG-IUS; contraceptive pill; hormonal contraception; ovarian reserve markers

Mesh:

Substances:

Year:  2019        PMID: 31852271     DOI: 10.1080/13625187.2019.1702158

Source DB:  PubMed          Journal:  Eur J Contracept Reprod Health Care        ISSN: 1362-5187            Impact factor:   1.848


  11 in total

1.  Duration, recency, and type of hormonal contraceptive use and antimüllerian hormone levels.

Authors:  Lia A Bernardi; Marissa Steinberg Weiss; Anne Waldo; Quaker Harmon; Mercedes R Carnethon; Donna D Baird; Lauren A Wise; Erica E Marsh
Journal:  Fertil Steril       Date:  2021-03-19       Impact factor: 7.490

2.  Influence of Menstrual Cycle or Hormonal Contraceptive Phase on Energy Intake and Metabolic Hormones-A Pilot Study.

Authors:  Johanna K Ihalainen; Ida Löfberg; Anna Kotkajuuri; Heikki Kyröläinen; Anthony C Hackney; Ritva S Taipale-Mikkonen
Journal:  Endocrines       Date:  2021-04-16

3.  Improving Reporting of Clinical Studies Using the POSEIDON Criteria: POSORT Guidelines.

Authors:  Sandro C Esteves; Alessandro Conforti; Sesh K Sunkara; Luigi Carbone; Silvia Picarelli; Alberto Vaiarelli; Danilo Cimadomo; Laura Rienzi; Filippo Maria Ubaldi; Fulvio Zullo; Claus Yding Andersen; Raoul Orvieto; Peter Humaidan; Carlo Alviggi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-19       Impact factor: 5.555

Review 4.  Clinical Use of Progestins and Their Mechanisms of Action: Present and Future (Review).

Authors:  T A Fedotcheva
Journal:  Sovrem Tekhnologii Med       Date:  2021-02-28

Review 5.  Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS.

Authors:  Ewa Rudnicka; Michał Kunicki; Anna Calik-Ksepka; Katarzyna Suchta; Anna Duszewska; Katarzyna Smolarczyk; Roman Smolarczyk
Journal:  Int J Mol Sci       Date:  2021-11-19       Impact factor: 5.923

Review 6.  Hormonal Stimulation of Human Ovarian Xenografts in Mice: Studying Folliculogenesis, Activation, and Oocyte Maturation.

Authors:  Monica Anne Wall; Vasantha Padmanabhan; Ariella Shikanov
Journal:  Endocrinology       Date:  2020-12-01       Impact factor: 4.736

7.  Evidence of profound ovarian suppression on combined hormonal contraception resulting in dramatically different ovarian reserve testing and oocyte retrieval outcomes: case report and review of the literature.

Authors:  Chelsea W Fox; Jamie Stanhiser; Alexander M Quaas
Journal:  F S Rep       Date:  2020-09-02

8.  Case for combined hormonal contraception holiday in fertility preservation patients.

Authors:  Jason Franasiak
Journal:  F S Rep       Date:  2020-09-08

Review 9.  Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function.

Authors:  Loes M E Moolhuijsen; Jenny A Visser
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

10.  The effect of prophylactic bilateral salpingectomy on ovarian reserve in patients who underwent laparoscopic hysterectomy.

Authors:  Shizhuo Wang; Jiahui Gu
Journal:  J Ovarian Res       Date:  2021-06-29       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.